IP Library Granted Patent US 10,696,732
Granted Patent B2
US 10,696,732 · App. 15/979,319 · Granted Jun 30, 2020

Albumin variants

Inventors: Darrell Sleep (Nottingham, GB); Andrew Plumridge (Derbyshire, GB); Jason Cameron (Nottingham, GB); Inger Sandlie (Oslo, NO); Jan Terje Andersen (Oslo, NO); Esben Peter Friis (Herlev, DK)
Assignee: ALBUMEDIX, LTD
C07K14/765A61K45/06C07K14/54C07K2319/20C07K2319/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,696,732
App. No.
15/979,319
Granted
Jun 30, 2020
Kind
B2
Abstract

The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.

Claims (16)

1. A method for preparing a variant of albumin, fragment thereof or a fusion polypeptide comprising said variant albumin or a fragment thereof, comprising the following steps:

a) selecting a nucleic acid encoding the albumin, fragment thereof or fusion polypeptide having a substitution in SEQ ID NO: 2 selected among:

Q580 I, K, M, and V;

b) introducing the nucleic acid of step a) into a suitable host cell;

c) growing the host cell in a growth medium under conditions leading to expression of the variant of albumin, fragments thereof or the fusion polypeptide comprising said variant albumin or fragment thereof; and

d) recovering the variant of albumin, fragment thereof or the fusion polypeptide comprising said variant albumin or fragment thereof from the growth medium;

wherein the variant of albumin, fragment thereof or the fusion polypeptide comprising said variant albumin or fragment thereof has an increased plasma half-life and increased binding affinity to neonatal Fc receptor (FcRn) as compared with an albumin, fragments thereof or a fusion polypeptide, respectively, that is the same except it has a Q at position 580.

2. The method of claim 1 , wherein the substitution is Q580I.

3. The method of claim 1 , wherein the substitution is Q580K.

4. The method of claim 1 , wherein the substitution is Q580M.

5. The method of claim 1 , wherein the substitution is Q580V.

6. The method of claim 1 , wherein the variant of albumin, fragment thereof or the fusion polypeptide comprising said variant albumin or fragment thereof has at least 95% sequence identity to SEQ ID NO: 2.

7. The method of claim 1 , wherein the variant of albumin, fragment thereof or the fusion polypeptide comprising said variant albumin or fragment thereof has at least 98% sequence identity to SEQ ID NO: 2.

8. The method of claim 1 , wherein the variant of albumin, fragment thereof or the fusion polypeptide comprising said variant albumin or fragment thereof comprises one or more amino acid alterations in SEQ ID NO:2 that generate a thiol group on the surface of the albumin, fragment thereof or the fusion polypeptide comprising said variant albumin or fragment thereof, wherein the one or more amino acid alterations is selected from:

L585C, D1C, A2C, D562C, A364C, A504C, E505C, T79C, E86C, D129C, D549C, A581C, D121C, E82C, S270C, A578C, L595LC, D1DC, A2AC, D562DC, A364AC, A504AC, E505EC, T79TC, E86EC, D129DC, D549DC, A581AC, D121DC, E82EC, S270SC, A579AC, C360*, C316*, C75*, C168*, C558*, C361*, C91*, C124*, C169* and C567*;

wherein * is an amino acid deletion.

Assignments (8)
CORRECTIVE ASSIGNMENT TO CORRECT THE THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 68165 FRAME: 276. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 9, 2024
From: ALBUMEDIX LTD
To: SARTORIUS ALBUMEDIX LIMITED
Reel/Frame 068526/0034 →
CHANGE OF NAME Recorded Aug 2, 2024
From: ALBUMEDIX LTD
To: SARTORIUS ALBUMEDIX LIMITED
Reel/Frame 068165/0276 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2019
From: SANDLIE, INGER; ANDERSEN, JAN TERJE
To: UNIVERSITY OF OSLO
Reel/Frame 048319/0903 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2019
From: NOVOZYMES A/S; NOVOZYMES BIOPHARMA UK LIMITED; UNIVERSITY OF OSLO
To: NOVOZYMES BIOPHARMA DK A/S
Reel/Frame 048322/0949 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2019
From: NOVOZYMES BIOPHARMA DK A/S
To: ALBUMEDIX A/S
Reel/Frame 048329/0475 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2019
From: FRIIS, ESBEN PETER
To: NOVOZYMES A/S
Reel/Frame 048320/0674 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2019
From: PLUMRIDGE, ANDREW; CAMERON, JASON; SLEEP, DARRELL
To: NOVOZYMES BIOPHARMA UK LIMITED
Reel/Frame 048319/0615 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2018
From: NOVOZYMES BIOPHARMA DK A/S (BI-NAME ALBUMEDIX A/S)
To: ALBUMEDIX LTD
Reel/Frame 046170/0127 →
Priority Claims (2)
EP 09174698 · Oct 30, 2009 · regional
EP 10174162 · Aug 26, 2010 · regional
Continuity (6)
Division 14863719 · Sep 24, 2015
Division 14262244 · Apr 25, 2014
Division 13504326
Provisional Application 61348001 · May 25, 2010
Provisional Application 61327171 · Apr 23, 2010
Related Publication 20180265570A1 · Sep 20, 2018